Durvalumab, sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. It was developed by Medimmune/AstraZeneca. From Wikipedia
A phase 3 clinical trial shows durvalumab reduces cancer recurrence risk by a third and increases two-year survival rates for patients with advanced bladder cancer.
